Targeting IL-6 in the Treatment of Uveitic Macular Edema - Scorecard - MDSpire

Targeting IL-6 in the Treatment of Uveitic Macular Edema

  • By

  • Rahul Khurana, MD

  • Michael A. Singer, MD

  • January 1, 2026

  • 5 min

Share

Clinical Scorecard: Targeting IL-6 in the Treatment of Uveitic Macular Edema

At a Glance

CategoryDetail
ConditionUveitic Macular Edema
Key MechanismsElevated IL-6 levels lead to corneal permeability, macular edema, and inflammation.
Target PopulationPatients with uveitic macular edema.
Care SettingOphthalmology clinics and research settings.

Key Highlights

  • Vamikibart targets IL-6 and shows promise in treating uveitic macular edema.
  • Phase 3 trials (MEERKAT and SANDCAT) demonstrated significant visual acuity improvement.
  • Low rates of intraocular inflammation and cataract observed with vamikibart.

Guideline-Based Recommendations

Diagnosis

  • Assess visual acuity and retinal anatomy in patients with uveitis.

Management

  • Consider vamikibart as an alternative to steroids for patients with persistent macular edema.

Monitoring & Follow-up

  • Monitor visual acuity and intraocular pressure post-injection.

Risks

  • Be aware of potential side effects such as intraocular inflammation and cataract.

Patient & Prescribing Data

Approximately 480 patients randomized in clinical trials.

Vamikibart showed sustained IL-6 suppression for up to 6 months.

Clinical Best Practices

  • Utilize vamikibart for patients with steroid-related complications.
  • Evaluate the need for repeat injections based on individual patient response.

Related Resources & Content

Original Source(s)

Targeting IL-6 in the Treatment of Uveitic Macular Edema

  • by Rahul Khurana, MD, Michael A. Singer, MD

  • January 1, 2026

Related Content

Smoking Doubles Risk of Vision Loss

New research indicates smoking doubles the risk of multiple sight-threatening conditions

  • May 15, 2026

  • 3 min
Treatment Strategies in Endogenous Fungal Endophthalmitis

Management of endogenous fungal endophthalmitis is complex, with wide variation in treatment strategies. Systemic markers of disease appear to influence the choice of initial therapy more than ocular findings. Although no definitive evidence favors IV over oral systemic therapy, a comprehensive, multidisciplinary approach that considers ocular involvement is essential to optimize patient outcomes in EFE.

Herpetic Eye Disease Is Not a Single Event

Joseph P. Shovlin, OD, FAAO, reviewed diagnosis, management, and emerging evidence related to chronic herpetic eye disease prevention at Optometry's Meeting 2026.